Latest news with #AMF
Business Wire
2 days ago
- Business
- Business Wire
GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million
PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the " Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a private placement of EUR 3,908,715.39 subscribed by a limited number of investors (the ' Private Placement '). ' We would like to thank our existing shareholders for their continued support, as well as the new international investors who have joined us in this important financing round, ' commented Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. ' The investment reflects the market's recognition of GenSight's unique position and the significant potential of our therapeutic programs. With this funding, we remain well-positioned to execute on our strategic objectives and advance our regulatory initiatives, with the upcoming opening of the French Named Patient Access (AAC) program representing a key inflection point for the company.' The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des marchés financiers – the ' AMF '). However, in accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the ' Prospectus Regulation '), the Company has filed with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the ' Information Document ') for the purpose of the listing on the regulated market of Euronext in Paris (' Euronext Paris ') of the Offered Shares, the Pre-Funded Warrant Shares and the Investor Warrant Shares (as defined below) to be issued in the context of the Private Placement. Copies of the Information Document are available free of charge on the Company's website at and on the AMF's website at Use of proceeds The Company intends to use the net proceeds from the Private Placement to finance, for up to approximately 77%, the continued development of LUMEVOQ ®, the Company's most advanced Phase III drug candidate. In particular, the funds raised will help ensure the Company's operational continuity and the finalization of manufacturing transfer activities and secure the preparations for the anticipated opening of the AAC program in France and the initiation of the Phase III study (RECOVER). The balance will be used to meet certain financial obligations of the Company (including the forthcoming redemption payment of the convertible bonds subscribed by Heights Capital Management, Inc., via CVII Investment, Inc.). This will extend the Company's cash runway from mid-July 2025 to early October 2025. " The Private Placement represents a strong vote of confidence from both our existing investors and new international partners in GenSight's compelling value proposition and robust asset portfolio,' noted Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics. ' The successful completion of this financing provides us with the operational runway to early October 2025. The opening of the AAC program in France is planned in Q4 2025. Then, from October 2025 onwards, the indemnity from the AAC program will establish a clear cash pathway for the months ahead. This strategic funding enables us to maintain our disciplined approach to our regulatory pathway." Terms and conditions of the Private Placement The Private Placement was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of: 21,251,267 ordinary shares (actions ordinaires), par value €0.025 per share of the Company (the " Offered Shares"); 1,850,000 pre-funded warrants (the " Offered Pre-Funded Warrants") giving the right to subscribe to 1,850,000 additional ordinary shares (the " Pre-Funded Warrant Shares"); and 23,101,267 warrants (the " Offered Investor Warrants") giving the right to subscribe to 23,101,267 additional ordinary shares (the " Investor Warrant Shares"). Investors had the choice to subscribe for two 'units' composed of: Offered Shares to which Offered Investor Warrants were attached (the " ABSA"), with one Offered Investor Warrant attached to each Offered Share, or Offered Pre-Funded Warrants to which Offered Investor Warrants were attached (the " Pre-paid Units"), with one Offered Investor Warrant attached to each Offered Pre-Funded Warrant. Each Offered Pre-Funded Warrant gives the investor the right to subscribe to one Pre-Funded Warrant Share, and each Offered Investor Warrant gives the investor the right to subscribe to One Investor Warrant Share. The Offered Investor Warrants attached to the Offered Shares and to the Offered Pre-Funded Warrants are identical and thus fungible when they are detached from the Offered Shares and the Offered Pre-Funded Warrants, upon issuance. The Pre-Funded Warrant Shares and the Investor Warrant Shares (together, the " New Shares") are fungible with the Company's existing ordinary shares of €0.025 par value. The launch of the Private Placement was decided on June 30, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to her by the Company's board of directors (the ' Board of Directors ') on June 19 and June 30, 2025. The Board of Directors acted pursuant to the delegation of competence granted to it under the 24 th resolution of the Company's shareholders on May 13, 2025 (the ' General Meeting '). The ABSA and the Pre-paid Units were issued in a capital increase with cancellation of shareholders' preferential subscription rights for the benefit of investors within the category of persons defined by the 24 th resolution of the General Meeting, in accordance with Article L. 225-138 of the French Commercial Code. The issue price of one ABSA is EUR 0.17. The issue price of one Pre-paid Unit is EUR 0.16. The exercise price of one Offered Investor Warrant is EUR 0.21 per Investor Warrant Share. The exercise price of one Offered Pre-Funded Warrant is EUR 0.01 per Pre-Funded Warrant Share. The EUR 0.17 issue price on one ABSA represents a facial discount of 15.63% (i.e., EUR 0.0315) to the closing price of the GenSight shares on Euronext Paris on the day of the determination of the issue price, i.e., EUR 0.2015 on June 30, 2025 (the ' Reference Price '). The exercise price of the Offered Investor Warrant represents a 4.22% (i.e., EUR 0.0085) premium to the Reference Price. The issue price of an ABSA, less the EUR 0.0546 theoretical value of the Offered Investor Warrant attached to it 1, plus the exercise price of such Offered Investor Warrant, represents a total 19.26% discount to the Reference Price for each of the two New Shares issued (the Offered Share and the Investor Warrant Share), consistent with the maximum discount authorized by the General Meeting pursuant to its 24 th resolution. The EUR 0.16 issue price of one Pre-paid Unit, less the EUR 0.0546 theoretical value of the Offered Investor Warrant attached to it 2, plus the exercise price of the Offered Pre-Funded Warrant and the exercise price of the Offered Investor Warrant, represents a total 19.26% discount to the Reference Price for each of the two New Shares issued (the Pre-Funded Warrant Share and the Investor Warrant Share), consistent with the maximum discount authorized by the General Meeting pursuant to its 24 th resolution. The Offered Pre-Funded Warrants may be exercised at any time within 60 months of their issuance. The Offered Investor Warrants may be exercised at any time within 60 months of their issuance. In the event all Offered Investor Warrants and all Offered Pre-Funded Warrants are exercised, their exercise will generate additional gross proceeds of EUR 4,869,766.07 (i.e., EUR 18,500,00 for the Pre-Funded Warrant Shares and EUR 4,851,266.07 for the Investor Warrant Shares). Impact of the Private Placement on the Company's shareholding Following the issuance of the Offered Shares, the Company's total share capital will be EUR 3,817,944.05 (composed of 152,717,762 ordinary shares). If all the Offered Pre-Funded Warrants are exercised, and thus all the Pre-Funded Warrant Shares issued, the Company's total share capital will be EUR 3,864,194.05 (composed of 154,567,762 ordinary shares). If all the Offered Investor Warrants are exercised, and thus all the Investor Warrants Shares issued, the Company's total share capital will be EUR 4,441,725.725 (composed of 177,669,029 ordinary shares). Please see sections 19.1.3 and 19.1.4 of GenSight's 2024 Universal Registration Document for a description of the securities issued by GenSight and giving access to its capital. To the Company's knowledge, immediately prior to completion of the Private Placement, the breakdown of the Company's share capital was as follows: To the Company's knowledge, immediately after the completion of the Private Placement and the issuance of the Offered Shares, the breakdown of the Company's share capital will be as follows: To the Company's knowledge, after the completion of the Private Placement and the issuance of the Offered Shares and all Pre-Funded Warrant Shares upon exercise of all Offered Pre-Funded Warrants, the breakdown of the Company's share capital will be as follows: To the Company's knowledge, after the completion of the Private Placement and the issuance of the Offered Shares and all Pre-Funded Warrant Shares upon exercise of all Offered Pre-Funded Warrants and the issuance of all Investor Warrant Shares upon exercise of all Offered Investor Warrants, the breakdown of the Company's share capital will be as follows: On the basis of the share capital of the Company immediately before completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company's share capital at that time and who did not participate will stand at: 0.86% on a non-diluted basis and 0.51% on a diluted basis immediately after the completion of the Private Placement and the issuance of the Offered Shares, 0.85% on a non-diluted basis and 0.51% on a diluted basis after the completion of the Private Placement and the issuance of the Offered Shares and all Pre-Funded Warrant Shares upon exercise of all Offered Pre-Funded Warrants, and 0.74% on a non-diluted basis and 0.51% on a diluted basis after the completion of the Private Placement and the issuance of the Offered Shares and all Pre-Funded Warrant Shares upon exercise of all Offered Pre-Funded Warrants and the issuance of all Investor Warrant Shares upon exercise of all Offered Investor Warrants. Admission to trading of the New Shares, the Offered Pre-Funded Warrants and the Offered Investor Warrants The Offered Shares are expected to be admitted to trading on Euronext Paris on July 3, 2025. The Offered Investor Warrants are expected to be admitted to trading on the Euronext Growth market in Paris (" Euronext Growth Paris") on or prior to July 11, 2025. The Offered Pre-Funded Warrants will not be admitted to trading on any venue. The Pre-Funded Warrant Shares and the Investor Warrant Shares will be admitted to trading on Euronext Paris as they are issued following the exercise of the corresponding warrants. The New Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0013183985 / SIGHT. Lock-up commitments The Company has signed a lock-up commitment pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. The directors and officers of the Company have signed a lock-up commitment pursuant to which they have agreed to a lock-up period of 60 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. Financial intermediaries Maxim Group, LLC acted as sole placement agent (the ' Placement Agent ') for the Private Placement in the United States, pursuant to an agreement entered into between the Company and the Placement Agent. Indicative timetable Decisions of the Board of Directors deciding the principle of the Private Placement and delegating to the Chief Executive Officer the necessary powers to implement the Private Placement. June 30, 2025 Decision of the Chief Executive Officer setting the terms and conditions of the Private Placement. July 1, 2025 Publication of this press release. July 1, 2025 Publication of the Information Document July 3, 2025 Publication of the Euronext notice of admission of the Offered Shares to trading on Euronext Paris. July 3, 2025 Settlement-delivery of the ABSAs and the Pre-paid Units- Detachment of the Offered Pre-Funded Warrants and the Offered Investor Warrants - Start of trading of the Offered Shares on Euronext Paris. July 11 at the latest, 2025 Admission of the Offered Investor Warrants on Euronext Growth Paris Expand Update on the Company's financial position As of May 31, 2025, the Company's cash and cash equivalents amounted to €0.9 million, virtually unchanged from March 31, 2025. The Company received EUR 0.7 million in Research Tax Credit (CIR) at the end of May 2025, with the balance of EUR 0.4 million expected in July 2025. For the record, the Company's financial debt includes loans guaranteed by the French government, a loan from the EIB, convertible bonds held by Heights Capital and Sight Again repayable advances, totaling EUR 25 million (nominal and interest, undiscounted value) as of May 31, 2025. This amount does not take into account (i) the close to EUR 4 million private placement announced in this press release, (ii) the repayment in principal of EUR 0.7 million on the convertible bonds held by Heights Capital through offset against their subscription in the aforementioned private placement, and (iii) the repayment of the outstanding balance of EUR 0.5 million in respect of the loans guaranteed by the French government described in section 8.3 of the 2024 URD. The settlement of this balance will end the default situation described in the 2024 URD. However, this default, through cross-default or cross-acceleration clauses, could have triggered the acceleration of certain other financial obligations of the Company. To date, no lender has given notice to the Company or formally demanded the acceleration of other financial debts. Based on current operations, current projections and this private placement of close to EUR 4 million, available cash will enable operations to continue until early October 2025. However, the Company's current resources remain insufficient to cover its operating needs for the next 12 months. In addition, the Company anticipates the launch of the AAC program no later than the fourth quarter of 2025. This launch remains subject to the ANSM's approval of a targeted dose-ranging study. The Company has submitted a preliminary study design to the agency and plans to finalize the study protocol within this timeframe. Once operational, this program should contribute to supporting clinical and regulatory activities. The Company has put in place a financing solution by mobilizing invoices related to AAC treatments within a very short time frame. Once the AAC program is operational, the Company will have a cash horizon of more than 12 months. The Company is implementing a financing strategy aimed at (i) ensuring the continuity of its operations until the start of the AAC program, (ii) preparing for the launch of the global Phase III clinical trial, and (iii) supporting the filing of the marketing authorization application with the MHRA in the United Kingdom for LUMEVOQ®. It is actively pursuing several financing options, including non-dilutive financing such as licensing agreements outside North America and Europe, partnerships, and potential mergers and acquisitions. Risk factors The Company draws the attention of the public to the risk factors relating to the Company and its business described in its 2024 Universal Registration Document, which is available free of charge on the Company's website ( , as amended by the Information Document. In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of GenSight diluted, and this shareholding may also be further diluted in the event of the exercise of the Offered Investor Warrants, as well as in the event of new securities transactions. The volatility and liquidity of GenSight shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price. About GenSight Biologics S.A. GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Disclaimer Not for release, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South Africa. This press release and the information contained herein do not contain or constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for securities in the United States of America or in any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act, or under the securities laws of any state or other jurisdiction of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or any other jurisdiction of the United States. GenSight does not intend to make a public offering of the securities in the United States of America. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. Forward-Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds of the Private Placement; the anticipated cash runway of the Company; and future expectations, plans and prospects of the Company. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' and 'future' or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed Private Placement and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the filings the Company makes with the AMF from time to time. The Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. 1 Black & Scholes calculation, with an annual volatility of 28.32%. 2 Idem. 3 The number of shares contained in the table includes 85,702,922 shares that may be issued by the Company further to the exercise of the remaining share warrants, founders share warrants, free shares and stock options outstanding. 4 Sofinnova Partners: French management company located at 7-11 boulevard Haussmann, 75009 Paris, France, which manages Sofinnova Crossover I SLP. 5 Invus: a Bermudian company located at Clarendon House, 2 Church Street, Hamilton HM 11 Bermuda. Pursuant to the provisions of Article L. 233-9 I, 4° bis of the French Commercial Code, Invus has stated that they hold 6,360,058 shares of GENSIGHT BIOLOGICS S.A. as a result of holding "contracts for differences" ("CFDs") maturing on January 3, 2034, covering an equivalent number of GENSIGHT BIOLOGICS S.A. shares, to be settled in cash. 6 UPMC: a non-profit organization located 6425, Penn Avenue, Suite 200, Pittsburgh, Pennsylvania, United States of America. 7 Heights Capital: a Cayman Islands exempted company located PO Box 309GT, Ugland House South Church Street, George Town Grand Cayman, Cayman Islands. 8 The number of shares contained in the table includes 73,202,953 shares that may be issued by the Company further to the exercise of the remaining share warrants, founders share warrants, free shares and stock options outstanding.
Cision Canada
2 days ago
- Business
- Cision Canada
Coming into force of the Regulation respecting complaint processing and dispute resolution in the financial sector
MONTRÉAL, /CNW/ - The Regulation respecting complaint processing and dispute resolution in the financial sector, published on February 15, 2024, will come into force on July 1, 2025. This Regulation of the Autorité des marchés financiers (AMF) is intended to harmonize the way complaints are processed, to the benefit of Québec financial consumers. The Regulation establishes standards to enhance transparency and the fair processing of consumer complaints in Québec. It applies to financial institutions, financial intermediaries and credit assessment agents with activities in Québec. The Regulation draws from domestic and international best practices and also reflects stakeholder input from two important consultations that helped improve the content. The Regulation establishes a common set of rules, obligations and practices for the financial sector, particularly with respect to the timeframes to be observed when handling consumer complaints. The coming into force of the Regulation coincides with the deployment of the AMF's 2025-2029 Strategic Plan (in French only), whose orientations include enhancing the consumer experience. The Regulation introduces significant changes for the financial sector. A number of tools are available to assist firms in understanding its scope and achieving compliance. About the AMF In its role as regulator, the Autorité des marchés financiers acts to maintain a financial sector that is dynamic, operates with integrity and warrants public confidence. It regulates, in whole or in part, activities in the following sectors: insurance, securities and derivatives, distribution of financial products and services, deposit institutions, mortgage brokerage and credit assessment.
Business Wire
2 days ago
- Business
- Business Wire
Notification of Availability of Rémy Cointreau
PARIS--(BUSINESS WIRE)--Regulatory News: Rémy Cointreau's (Paris:RCO) 2024-25 Universal Registration Document was filed with the French Financial Markets Authority (AMF) in the European Single Electronic Format (ESEF) on Monday, June 30, 2025, under the reference number D.25-0497. The document is publicly available under the current regulatory conditions and can be accessed on Rémy Cointreau's website at in both French and English, within the Finance / Publications and Events / Annual reports and Registration documents' section. It is also available on the AMF website at in French. The Universal Registration Document includes in particular: the annual financial report as of March 31, 2025, the report of the Board of Directors on corporate governance, the Statutory Auditors' reports, the statement of Auditors' fees, the description of the share buyback program the sustainability report. About Rémy Cointreau All around the world, there are clients seeking exceptional experiences; clients for whom a wide range of terroirs means a variety of flavors. Their exacting standards are proportional to our expertise – the finely-honed skills that we pass down from generation to generation. The time these clients devote to drinking our products is a tribute to all those who have worked to develop them. It is for these men and women that Rémy Cointreau, a family-owned French Group, protects its terroirs, cultivates exceptional multi-centenary spirits and undertakes to preserve their eternal modernity. The Group's portfolio includes 14 singular brands, such as the Rémy Martin and LOUIS XIII cognacs, and Cointreau liqueur. Rémy Cointreau has a single ambition: becoming the world leader in exceptional spirits. To this end, it relies on the commitment and creativity of its 1,856 employees and on its distribution subsidiaries established in the Group's strategic markets. Rémy Cointreau is listed on Euronext Paris.
Business Wire
24-06-2025
- Business
- Business Wire
Aelis Farma: Availability of the Description of the Share Buyback Program
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of May 27, 2025. Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on May 27, 2025, in its 16 th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with the law. In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the description of the share buyback program is included in the Company's Universal Registration Document, which has been filed with the AMF on April 28, 2025, under number D.25-0314. This document is available on the Company's website at: *** About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB 1 receptor of the endocannabinoid system (CB 1 -SSi). CB 1 -SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB 1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB 1 -SSi appear to selectively inhibit the disease-related activity of the CB 1 receptor without disrupting its normal physiological activity. CB 1 -SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB 1 -SSi in humans. The Company also has a portfolio of new innovative CB 1 -SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB 1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB 1 -SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB 1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4 Ticker: AELIS C Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D.25-0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
Yahoo
24-06-2025
- Business
- Yahoo
Aelis Farma: Availability of the Description of the Share Buyback Program
BORDEAUX, France, June 24, 2025--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of May 27, 2025. Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on May 27, 2025, in its 16th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with the law. In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the description of the share buyback program is included in the Company's Universal Registration Document, which has been filed with the AMF on April 28, 2025, under number D.25-0314. This document is available on the Company's website at: *** About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi appear to selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. CB1-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB1-SSi in humans. The Company also has a portfolio of new innovative CB1-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB1-SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4Ticker: AELISC Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D.25-0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements. View source version on Contacts AELIS FARMA Pier Vincenzo PiazzaChief Executive Officercontact@ NewCap Dusan Oresansky / Aurélie ManavarereInvestor Relationsaelis@ +33 1 44 71 94 92 NewCap Arthur RouilléMedia Relationsaelis@ +33 1 44 71 00 15 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
